LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

Home・Listă Acțiuni・Cytokinetics Inc

Cytokinetics Inc

Deschisă

SectorSănătate

73.3 -4.54

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

73.7

Maxim

76.34

Indicatori cheie
By Trading Economics
Venit	-23M -206M
Vânzări	1.6M 19M
EPS	-1.67
Marjă de profit	-1,064.485
Angajați	673
EBITDA	112K -180M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+30.73% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.2B 10B
Deschiderea anterioară	77.84
Închiderea anterioară	73.3

Sentimentul știrilor

By Acuity

26%

74%

44 / 344 Clasament în Healthcare

Cytokinetics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mai 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 mai 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 mai 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 mai 2026, 22:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 mai 2026, 23:08 UTC

Achiziții, Fuziuni, Preluări

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mai 2026, 23:06 UTC

Achiziții, Fuziuni, Preluări

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mai 2026, 20:53 UTC

Câștiguri

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mai 2026, 20:11 UTC

Câștiguri

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 19:47 UTC

Câștiguri

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mai 2026, 19:05 UTC

Achiziții, Fuziuni, Preluări

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mai 2026, 18:12 UTC

Achiziții, Fuziuni, Preluări

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mai 2026, 17:55 UTC

Câștiguri

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mai 2026, 17:00 UTC

Câștiguri

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Cytokinetics Inc Așteptări

Obiectiv de preț

By TipRanks

30.73% sus

Prognoză pe 12 luni

Medie 100.35 USD 30.73%

Maxim 140 USD

Minim 67 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCytokinetics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

18 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 18 analiști care au acordat evaluări ale acțiunilor Cytokinetics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

44 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.